 |
Return Create A Forum - Home |
 |
--------------------------------------------------------- |
|
MS Speaks |
 |
https://msspeaks.createaforum.com |
|
--------------------------------------------------------- |
|
***************************************************** |
|
Return to: OCREVUS (ocrelizumab) |
|
***************************************************** |
|
#Post#: 3213-------------------------------------------------- |
|
Fatal PML case in 78-year-old patient on Ocrevus monotherapy |
|
By: agate Date: March 16, 2021, 5:55 pm |
|
--------------------------------------------------------- |
|
From JAMA Neurology (March 16, 2021), "Progressive multifocal |
|
leukoencephalopathy in a patient with progressive multiple |
|
sclerosis treated with ocrelizumab monotherapy": |
|
http://bit.ly/3eQm9ii |
|
#Post#: 3214-------------------------------------------------- |
|
MedPage Today) PML reported in ocrelizumab-treated MS patient |
|
By: agate Date: March 18, 2021, 1:28 am |
|
--------------------------------------------------------- |
|
From MedPage Today (March 17, 2021)--"PML reported in |
|
ocrelizumab-treated MS patient": |
|
https://www.medpagetoday.com/neurology/multiplesclerosis/91647 |
|
#Post#: 3216-------------------------------------------------- |
|
(Medscape) First case of PML associated with ocrelizumab monothe |
|
rapy |
|
By: agate Date: March 20, 2021, 12:43 am |
|
--------------------------------------------------------- |
|
This is the third article I've found on this topic, and so far |
|
there is no indication of how long the patient had had MS. It |
|
might be helpful to know that. |
|
Medscape (March 29, 2021)--"First case of PML associated with |
|
ocrelizumab monotherapy": |
|
https://www.medscape.com/viewarticle/947765#vp_2 |
|
#Post#: 3219-------------------------------------------------- |
|
Re: Fatal PML case in 78-year-old patient on Ocrevus monotherapy |
|
By: agate Date: March 23, 2021, 1:10 am |
|
--------------------------------------------------------- |
|
The first article mentioned in this thread contains this |
|
information about the patient. |
|
[quote][font=Guardian TextSans Web]The patient had been |
|
diagnosed with MS almost 3 decades prior after developing |
|
gradual gait dysfunction and bilateral asymmetric leg weakness |
|
throughout several years. Despite continued slow gait worsening |
|
over years, he had not been treated with immunotherapy until |
|
ocrelizumab was approved by the US Food and Drug Administration |
|
for primary progressive MS in 2017. He began taking ocrelizumab |
|
at age 76 years soon after Food and Drug Administration |
|
approval. The patient�s JCV index was 2.48 prior to initiation, |
|
and the theoretical risk of PML was discussed prior to starting. |
|
He tolerated the treatments well but continued to exhibit |
|
worsening gait dysfunction.[/font][/quote][font=Guardian |
|
TextSans Web][/font] |
|
[font=Guardian TextSans Web][/size][/font] |
|
[font=Guardian TextSans Web][/size]One wonders why a patient of |
|
76 who has had PPMS for some 30 years would have been prescribed |
|
ocrelizumab.[/font] |
|
***************************************************** |
